CG Oncology, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -90.84% | -74.74% | -29.91% | -114.69% | -119.16% |
| Total Depreciation and Amortization | 444.87% | 3,404.17% | -- | 1,880.95% | 2,128.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 274.55% | 75.07% | 31.84% | 593.41% | 2,120.87% |
| Change in Net Operating Assets | 66.03% | -1,332.20% | -181.35% | -184.45% | 188.29% |
| Cash from Operations | -66.01% | -94.50% | -75.28% | -144.32% | -73.44% |
| Capital Expenditure | -3,242.86% | -1,800.00% | 96.65% | -9,800.00% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,074.24% | -79.14% | -779.31% | 15.95% | 103.92% |
| Cash from Investing | 2,062.62% | -79.28% | -792.39% | -52.99% | 103.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10,852.63% | 57,556.74% | -55.64% | 2,396.54% | -75.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 55.87% | 79.74% | -- | -- | -751.35% |
| Cash from Financing | 749.32% | 87,232.89% | -55.66% | 2,409.00% | -840.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.62% | 100.56% | -105.92% | 67.21% | 48.68% |